Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shot up 1.9% during mid-day trading on Friday . The stock traded as high as $5.89 and last traded at $5.32. 647,470 shares were traded during trading, a decline of 48% from the average session volume of 1,254,936 shares. The stock had previously closed at $5.22.
Analyst Ratings Changes
Several brokerages recently issued reports on CTOR. Maxim Group lowered shares of Citius Oncology from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Citigroup lowered shares of Citius Oncology to a "hold" rating in a research note on Friday, May 23rd.
Get Our Latest Report on Citius Oncology
Citius Oncology Stock Performance
The company's 50 day moving average is $1.75 and its 200-day moving average is $1.25. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.05 and a current ratio of 0.36.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Citius Oncology stock. Citadel Advisors LLC bought a new stake in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,699 shares of the company's stock, valued at approximately $26,000. Institutional investors and hedge funds own 70.52% of the company's stock.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Recommended Stories
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
